While it no longer generates the sales it once did, Pfizer's coronavirus lineup remains critical to its results. The past three years have been challenging for Pfizer (NYSE: PFE). Although Pfizer ...

Pfizer’s Debt figure was $61 Bil at the end of the most recent quarter, while its market capitalization is $133 Bil (as of 6/2/2025). This implies a poor Debt-to-Equity Ratio of 46.2% (vs. 19.9% ...

Pfizer (NYSE:PFE) announced robust sales for the antifungal drug Cresemba in partnership with Basilea Pharmaceutica Ltd, marking significant growth in key Asian markets. Despite this achievement ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s move for a lot less money.

Pfizer CEO Albert Bourla has slammed this decision and at a ... friend out of selfie with Brad Pitt before posting it to social media as she jokes she is going to make it her phone wallpaper; ...

The past three years have been challenging for Pfizer (NYSE: PFE).Revenue and earnings have moved in the wrong direction, as has the company's share price. The stock is down by 56% since 2022.

The past three years have been challenging for Pfizer (PFE 1.14%). Revenue and earnings have moved in the wrong direction, as has the company's share price. The stock is down by 56% since 2022.

Pfizer appears to be a very promising stock to buy if you're looking for income. That 7.3% dividend yield is terrific, and even if it gets slashed, it will likely still be substantial.

Lately, Pfizer (PFE-0.08%) and Prologis (PLD-0.32%) have been perfect examples of the trade-off between attractive yields and dividend growth. Pfizer offers a sky-high yield that's climbing slowly.

Recent research has linked Pfizer's widely-used Depo-Provera birth control shot to massively increased risk of developing brain tumors — and hundreds of women are suing the pharmaceutical giant ...

Wallpaper* launches Weekendpaper*, the new Saturday newsletter for the design-minded and the culturally curious. Embracing all Wallpaper* pillars – architecture, design & interiors, art & culture, ...

Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also underperformed the sector and the S&P 500, as seen in the chart below.